AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23977105 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of physicians
Number of subjects: 17
Study 23977105 — intervention group
Group type: COMPARATOR
Intervention: Control day (clerical work)
Number of subjects: 17
Study 20537762 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfurous, salty, bromic, iodic (SSBI) thermal water
Number of subjects: 80
Study 20537762 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (ISCS)
Number of subjects: 80
Study 19440013 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic mixture of local anesthetics cream (EMLA)
Number of subjects: 120
Study 19440013 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (DS)
Number of subjects: 120
Study 19440013 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA+DS
Number of subjects: 120
Study 19440013 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 120
Study 17848798 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantasy Therapy
Number of subjects: 0
Study 17848798 — intervention group
Group type: COMPARATOR
Intervention: Art Therapy (AT)
Number of subjects: 0
Study 17848798 — intervention group
Group type: COMPARATOR
Intervention: Placebo Group (PG)
Number of subjects: 0
Study 15278255 — intervention group
Group type: EXPERIMENTAL
Intervention: Continent women
Number of subjects: 103
Study 15278255 — intervention group
Group type: COMPARATOR
Intervention: Incontinent women
Number of subjects: 103
Study 11589647 — intervention group
Group type: EXPERIMENTAL
Intervention: Losigamone
Number of subjects: 16
Study 11589647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9010894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum and acupuncture
Number of subjects: 0
Study 9010894 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 0
Study 9010894 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of one active treatment and placebo
Number of subjects: 0
Study 7523909 — intervention group
Group type: EXPERIMENTAL
Intervention: Styrene and DCM exposure
Number of subjects: 46
Study 7523909 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=23)
Number of subjects: 46
Study 7523909 — intervention group
Group type: EXPERIMENTAL
Intervention: DCM exposure
Number of subjects: 46
Study 7523909 — intervention group
Group type: EXPERIMENTAL
Intervention: Styrene exposure
Number of subjects: 46
Study 3258069 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS to appropriate auricular points (Group 1, n = 15)
Number of subjects: 44
Study 3258069 — intervention group
Group type: COMPARATOR
Intervention: TENS to inappropriate (placebo) auricular points (Group 2, n = 14)
Number of subjects: 44
Study 3258069 — intervention group
Group type: COMPARATOR
Intervention: No TENS (Group 3, n = 15)
Number of subjects: 44
Study 30044349 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Faces Pain Scale-Revised (FPS-R)
Number of subjects: 257
Study 27570858 — intervention group
Group type: EXPERIMENTAL
Intervention: Miswak mouthwash
Number of subjects: 40
Study 27570858 — intervention group
Group type: EXPERIMENTAL
Intervention: Miswak toothpaste
Number of subjects: 40
Study 27570858 — intervention group
Group type: COMPARATOR
Intervention: Ordinary toothpaste
Number of subjects: 40
Study 27570858 — intervention group
Group type: COMPARATOR
Intervention: Ordinary toothpaste with normal saline
Number of subjects: 40
Study 26714845 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Incentives and Navigation (WIN) project including personal navigators, motivational interviewing, and a flexible wellness account
Number of subjects: 1250
Study 26714845 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided within Medicaid Managed Care
Number of subjects: 1250
Study 23982855 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg lidocaine and 100 % O(2) (group L)
Number of subjects: 205
Study 23982855 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl and a mixture of 67 % N(2)O/O(2) (group N)
Number of subjects: 205
Study 23982855 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg lidocaine and a mixture of 67 % N(2)O/O(2) (group LN)
Number of subjects: 205
Study 23982855 — intervention group
Group type: COMPARATOR
Intervention: NaCl and 100 % O(2) (group C)
Number of subjects: 205
Study 21761394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21761394 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg)
Number of subjects: 18
Study 21761394 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg) + Taurine (2 g)
Number of subjects: 18
Study 19388924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid simulation model (endovaginal ultrasound task trainer with high-fidelity mannequin)
Number of subjects: 45
Study 19388924 — intervention group
Group type: COMPARATOR
Intervention: Standard high-fidelity simulation (mannequin with static photo images)
Number of subjects: 45
Study 17145846 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mutagen sensitivity (cutoff > or =0.50 breaks per cell)
Number of subjects: 991
Study 17145846 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IGF-I levels
Number of subjects: 991
Study 17145846 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IGF-binding protein-3 levels
Number of subjects: 991
Study 17145846 — intervention group
Group type: EXPERIMENTAL
Intervention: High IGF-I level alone
Number of subjects: 991
Study 17145846 — intervention group
Group type: EXPERIMENTAL
Intervention: High mutagen sensitivity alone
Number of subjects: 991
Study 17145846 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high IGF-I level and high mutagen sensitivity
Number of subjects: 991
Study 14747687 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 g of fruits and vegetables
Number of subjects: 12
Study 14747687 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 g of fruits and vegetables
Number of subjects: 12
Study 14747687 — intervention group
Group type: COMPARATOR
Intervention: Basic diet (no fruits or vegetables)
Number of subjects: 12
Study 11763829 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Number of subjects: 170
Study 11763829 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle education
Number of subjects: 170
Study 8529054 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa (200 mg) + benserazide (50 mg)
Number of subjects: 15
Study 8529054 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 2203517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilutamide
Number of subjects: 203
Study 2203517 — intervention group
Group type: COMPARATOR
Intervention: Castration alone (Placebo)
Number of subjects: 203
Study 361207 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (progestogen group)
Number of subjects: 69
Study 361207 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo group)
Number of subjects: 69
Study 31185762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Ripening Double Balloon catheter (CRDB)
Number of subjects: 180
Study 31185762 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter
Number of subjects: 180
Study 31655626 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium plus valproic acid (Li/VPA)
Number of subjects: 64
Study 31655626 — intervention group
Group type: COMPARATOR
Intervention: Lithium plus carbamazepine (Li/CBZ)
Number of subjects: 64
Study 27120292 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-OSU6162 at a dose of 15 mg twice a day
Number of subjects: 64
Study 27120292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 27120292 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-OSU6162
Number of subjects: 64
Study 25520332 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg
Number of subjects: 344
Study 25520332 — intervention group
Group type: COMPARATOR
Intervention: Standard care (fluconazole, liposomal amphotericin B, or caspofungin)
Number of subjects: 344
Study 25520332 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 344
Study 25675661 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS)
Number of subjects: 130
Study 25675661 — intervention group
Group type: COMPARATOR
Intervention: Cold Instruments (CI)
Number of subjects: 130
Study 22035984 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS silane (ESPE‐Sil, 3M ESPE) applied to all specimens, left to react at 20°C for 2 min, followed by heat treatment at 38°C, 79°C, or 100°C for 1 min.
Number of subjects: 18
Study 22035984 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS silane with rinsing in hot water (B groups).
Number of subjects: 18
Study 22035984 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat treatments (G38, G79, G100).
Number of subjects: 18
Study 22035984 — intervention group
Group type: COMPARATOR
Intervention: Control group (GC) received no silane treatment.
Number of subjects: 18
Study 20705158 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive ring
Number of subjects: 524
Study 20705158 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive patch
Number of subjects: 524
Study 20705158 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper IUC
Number of subjects: 524
Study 20705158 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about IUC
Number of subjects: 524
Study 20705158 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about infertility and pain with IUC
Number of subjects: 524
Study 17572147 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (class III antiarrhythmic)
Number of subjects: 3028
Study 17572147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3028
Study 15925130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 498
Study 12032036 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of ropivacaine 1 mg/mL and fentanyl 2 microg/mL with epinephrine 2 microg/mL
Number of subjects: 12
Study 12032036 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion of ropivacaine 1 mg/mL and fentanyl 2 microg/mL without epinephrine
Number of subjects: 12
Study 9862082 — intervention group
Group type: COMPARATOR
Intervention: 2 mg haloperidol
Number of subjects: 100
Study 9862082 — intervention group
Group type: COMPARATOR
Intervention: 5 mg haloperidol
Number of subjects: 100
Study 9862082 — intervention group
Group type: COMPARATOR
Intervention: 5 mg d-amphetamine
Number of subjects: 100
Study 9862082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9862082 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine and haloperidol (in smokers subgroup)
Number of subjects: 100
Study 8908439 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon green laser photocoagulation
Number of subjects: 19
Study 8908439 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 19
Study 1650128 — intervention group
Group type: EXPERIMENTAL
Intervention: tetravalent rhesus rotavirus vaccine with small-volume (2.5-mL) antacid buffer
Number of subjects: 174
Study 1650128 — intervention group
Group type: EXPERIMENTAL
Intervention: tetravalent rhesus rotavirus vaccine with large-volume (30-mL) antacid buffer
Number of subjects: 174
Study 1650128 — intervention group
Group type: COMPARATOR
Intervention: tetravalent rhesus rotavirus vaccine alone
Number of subjects: 174
Study 1650128 — intervention group
Group type: EXPERIMENTAL
Intervention: tetravalent rhesus rotavirus vaccine with oral polio vaccine
Number of subjects: 174
Study 1650128 — intervention group
Group type: COMPARATOR
Intervention: oral polio vaccine serotype 1
Number of subjects: 174
Study 1650128 — intervention group
Group type: COMPARATOR
Intervention: oral polio vaccine serotype 2
Number of subjects: 174
Study 1650128 — intervention group
Group type: COMPARATOR
Intervention: oral polio vaccine serotype 3
Number of subjects: 174
Study 6613137 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 515
Study 6613137 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 515
Study 30859967 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine (40mg and 80mg)
Number of subjects: 464
Study 30859967 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine (open-label treatment)
Number of subjects: 464
Study 28857952 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional method focused on patient status reporting
Number of subjects: 0
Study 28857952 — intervention group
Group type: COMPARATOR
Intervention: Control instructional method
Number of subjects: 0
Study 27823710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) 1000 mg as a single infusion
Number of subjects: 32
Study 27823710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 27823710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) 1000 mg
Number of subjects: 32
Study 25024410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) salbutamol provocation at a dosage of 0.30 µg/min for 5 minutes
Number of subjects: 30
Study 23062392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 100 μg once daily
Number of subjects: 622
Study 23062392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 200 μg once daily
Number of subjects: 622
Study 23062392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 300 μg once daily
Number of subjects: 622
Study 23062392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 400 μg once daily
Number of subjects: 622
Study 23062392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 250 μg twice daily (active control)
Number of subjects: 622
Study 23062392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 622
Study 19787464 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidifier with conventional microbiologic filter (CMF-HH)
Number of subjects: 41
Study 19787464 — intervention group
Group type: COMPARATOR
Intervention: HME-Booster
Number of subjects: 41
Study 19787464 — intervention group
Group type: COMPARATOR
Intervention: Both humidifiers (CMF-HH and HME-Booster)
Number of subjects: 41
Study 17321243 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-stiffness colonoscope
Number of subjects: 335
Study 15381545 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% tacrolimus ointment plus 308-nm excimer laser therapy (group A)
Number of subjects: 14
Study 15381545 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser monotherapy (group B)
Number of subjects: 14
Study 15381545 — intervention group
Group type: COMPARATOR
Intervention: Untreated lesions (control group)
Number of subjects: 14
Study 11194214 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg repaglinide at mealtimes (increased to 1 mg after 4 weeks)
Number of subjects: 408
Study 11194214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study 9445234 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundoplication and antroplasty
Number of subjects: 15
Study 9100602 — intervention group
Group type: EXPERIMENTAL
Intervention: hCRH (1 microgram/kg) stimulation alone
Number of subjects: 14
Study 9100602 — intervention group
Group type: EXPERIMENTAL
Intervention: hCRH (1 microgram/kg) stimulation with 5% NaCl (0.06 mL.kg/min for 120 min)
Number of subjects: 14
Study 9100602 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic volume loading (0.9% NaCl, 12 mL.kg.60 min)
Number of subjects: 14
Study 9100602 — intervention group
Group type: COMPARATOR
Intervention: hCRH (1 microgram/kg) stimulation
Number of subjects: 14
Study 2516705 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and spironolactone (n = 15)
Number of subjects: 25
Study 2516705 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (n = 10)
Number of subjects: 25
Study 944395 — intervention group
Group type: EXPERIMENTAL
Intervention: Flufenamic acid (125 mg four to six times per attack)
Number of subjects: 26
Study 944395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 944395 — intervention group
Group type: COMPARATOR
Intervention: Common antimigraine drugs
Number of subjects: 26
Study 31537547 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 (1 million IU, subcutaneously every other day for 2 weeks, followed by a 2-week break)
Number of subjects: 60
Study 31537547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31327753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular Health Score (CHS) assessment
Number of subjects: 3492
Study 31327753 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation period since mid-2016
Number of subjects: 3492
Study 27792991 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 67
Study 27792991 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 67
Study 25450450 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional incentive (book voucher mailed with letter of invitation)
Number of subjects: 3334
Study 25450450 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional incentive (book voucher mailed on completion of the online survey)
Number of subjects: 3334
Study 25450450 — intervention group
Group type: COMPARATOR
Intervention: Control (no incentive)
Number of subjects: 3334
Study 24071925 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-shifting prism glasses while standing on the floor (Group 1)
Number of subjects: 3
Study 24071925 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-shifting prism glasses while on a balance board (Group 2)
Number of subjects: 3
Study 24071925 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-shifting prism glasses while on a balance board (Group 3)
Number of subjects: 3
Study 21353017 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia combined with intercostal nerve cryoanalgesia
Number of subjects: 42
Study 21353017 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia alone
Number of subjects: 42
Study 20854770 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antidepressant medication and cognitive-behavioral therapy focused on suicide prevention (Comb)
Number of subjects: 124
Study 20854770 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy focused on suicide prevention
Number of subjects: 124
Study 20854770 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medication
Number of subjects: 124
Study 16840826 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate altitude (MA) group (1700 m)
Number of subjects: 71
Study 16840826 — intervention group
Group type: COMPARATOR
Intervention: Low altitude (LA) group (200 m)
Number of subjects: 71
Study 16840826 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 12757090 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of intravitreal dexamethasone
Number of subjects: 56
Study 12757090 — intervention group
Group type: COMPARATOR
Intervention: No dexamethasone (control group)
Number of subjects: 56
Study 10794294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghajar Guide-assisted catheter placement
Number of subjects: 49
Study 10794294 — intervention group
Group type: COMPARATOR
Intervention: Freehand catheter placement
Number of subjects: 49
Study 9340059 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic asthma
Number of subjects: 43
Study 9340059 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic asthma
Number of subjects: 43
Study 9340059 — intervention group
Group type: COMPARATOR
Intervention: Sarcoidosis
Number of subjects: 43
Study 9340059 — intervention group
Group type: COMPARATOR
Intervention: Allergic alveolitis
Number of subjects: 43
Study 9340059 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 43
Study 8324945 — intervention group
Group type: EXPERIMENTAL
Intervention: DAB486IL‐2 (260 kU/kg/d)
Number of subjects: 45
Study 8324945 — intervention group
Group type: EXPERIMENTAL
Intervention: DAB486IL‐2 (130 kU/kg/d)
Number of subjects: 45
Study 8324945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 3462459 — intervention group
Group type: EXPERIMENTAL
Intervention: Certain therapies
Number of subjects: 0
Study 3462459 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunophenotype of ALL
Number of subjects: 0
Study 29678987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (Octafibrin/Fibryga; Octapharma) - 4g administered within 24 hours of cardiopulmonary bypass
Number of subjects: 1200
Study 29678987 — intervention group
Group type: COMPARATOR
Intervention: Cryoprecipitate - 10 units (dose-equivalent to 4g) administered within 24 hours of cardiopulmonary bypass
Number of subjects: 1200
Study 29678987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (Octafibrin/Fibryga; Octapharma)
Number of subjects: 1200
Study 29678987 — intervention group
Group type: COMPARATOR
Intervention: Cryoprecipitate
Number of subjects: 1200
Study 26648582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid-loaded dissolving microneedle patch
Number of subjects: 23
Study 26648582 — intervention group
Group type: COMPARATOR
Intervention: Control sample
Number of subjects: 23
Study 24772989 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational health care package
Number of subjects: 500
Study 24772989 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 500
Study 22583983 — intervention group
Group type: EXPERIMENTAL
Intervention: Jerte Valley cherry product
Number of subjects: 0
Study 22583983 — intervention group
Group type: COMPARATOR
Intervention: Placebo product
Number of subjects: 0
Study 19846474 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored smoking cessation program
Number of subjects: 194
Study 19846474 — intervention group
Group type: COMPARATOR
Intervention: Cluster membership
Number of subjects: 194
Study 17917552 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 200 mg/day
Number of subjects: 0
Study 17917552 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 400 mg/day
Number of subjects: 0
Study 17917552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0